Cargando…

Alport syndrome: Proteomic analysis identifies early molecular pathway alterations in Col4a3 knock out mice

AIM: Alport syndrome (AS) is the second most common hereditary kidney disease caused by mutations in collagen IV genes. Patients present with microhaematuria that progressively leads to proteinuria and end stage renal disease. Currently, no specific treatment exists for AS. Using mass spectrometry b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nicolaou, Orthodoxia, Kousios, Andreas, Sokratous, Kleitos, Potamiti, Louiza, Koniali, Lola, Neophytou, George, Papacharalampous, Revekka, Zanti, Maria, Ioannou, Kyriakos, Hadjisavvas, Andreas, Stingl, Christoph, Luider, Theo M., Kyriacou, Kyriacos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754404/ https://www.ncbi.nlm.nih.gov/pubmed/32743880 http://dx.doi.org/10.1111/nep.13764

Ejemplares similares

Biomarkers of systemic lupus erythematosus identified using mass spectrometry‐based proteomics: a systematic review
por: Nicolaou, Orthodoxia, et al.
Publicado: (2016)

Omega-3 fatty acids supplementation protects the retina from age-associated degeneration in aged C57BL/6J mice
por: Prokopiou, Ekatherine, et al.
Publicado: (2019)

Proteomic analysis in lupus mice identifies Coronin-1A as a potential biomarker for lupus nephritis
por: Nicolaou, Orthodoxia, et al.
Publicado: (2020)

Pharmacological Stimulation of Phagocytosis Enhances Amyloid Plaque Clearance; Evidence from a Transgenic Mouse Model of ATTR Neuropathy
por: Fella, Eleni, et al.
Publicado: (2017)

Patient-derived podocyte spheroids reveal new insights into the etiopathogenesis of Alport syndrome
por: Romero-Guevara, Ricardo, et al.
Publicado: (2023)

Risk factors for breast cancer brain metastases: a systematic review
por: Koniali, Lola, et al.
Publicado: (2020)

Observational study of health utilities in adult primary ciliary dyskinesia patients: preliminary data on associations with molecular diagnosis, clinical phenotype and HRQOL measures
por: Kouis, Panayiotis, et al.
Publicado: (2022)

Performance evaluation of pipelines for mapping, variant calling and interval padding, for the analysis of NGS germline panels
por: Zanti, Maria, et al.
Publicado: (2021)

Systemic Evaluation of Chimeric LNA/2′-O-Methyl Steric Blockers for Myotonic Dystrophy Type 1 Therapy
por: Christou, Melina, et al.
Publicado: (2020)

The BRCA1 Variant p.Ser36Tyr Abrogates BRCA1 Protein Function and Potentially Confers a Moderate Risk of Breast Cancer
por: Christou, Charita M., et al.
Publicado: (2014)

Progression of Alport Kidney Disease in Col4a3 Knock Out Mice Is Independent of Sex or Macrophage Depletion by Clodronate Treatment
por: Kim, Munkyung, et al.
Publicado: (2015)

Gold Nanobipyramids for Near-Infrared Fluorescence-Enhanced Imaging and Treatment of Triple-Negative Breast Cancer
por: Theodorou, Ioannis G., et al.
Publicado: (2023)

Intramuscular Evaluation of Chimeric Locked Nucleic Acid/2′OMethyl-Modified Antisense Oligonucleotides for Targeted Exon 23 Skipping in Mdx Mice
por: Georgiadou, Michaella, et al.
Publicado: (2021)

COL4A6 is dispensable for autosomal recessive Alport syndrome
por: Murata, Tomohiro, et al.
Publicado: (2016)

The mediterranean dietary pattern and breast cancer risk in Greek-Cypriot women: a case-control study
por: Demetriou, Christiana A, et al.
Publicado: (2012)

Novel mutations in COL4A3, COL4A4, and COL4A5 in Chinese patients with Alport Syndrome
por: Liu, Jian-Hong, et al.
Publicado: (2017)

Stbd1 promotes glycogen clustering during endoplasmic reticulum stress and supports survival of mouse myoblasts
por: Lytridou, Andria A., et al.
Publicado: (2020)

NGS Panel Testing of Triple-Negative Breast Cancer Patients in Cyprus: A Study of BRCA-Negative Cases
por: Zanti, Maria, et al.
Publicado: (2020)

Trimerization and Genotype–Phenotype Correlation of COL4A5 Mutants in Alport Syndrome
por: Kamura, Misato, et al.
Publicado: (2020)

Identification of 27 Novel Variants in Genes COL4A3, COL4A4, and COL4A5 in Lithuanian Families With Alport Syndrome
por: Cerkauskaite, Agne, et al.
Publicado: (2022)

Effect of heterozygous pathogenic COL4A3 or COL4A4 variants on patients with X‐linked Alport syndrome
por: Zhang, Yanqin, et al.
Publicado: (2019)

Genotype–phenotype correlations for COL4A3–COL4A5 variants resulting in Gly substitutions in Alport syndrome
por: Gibson, Joel T., et al.
Publicado: (2022)

Creation of X-linked Alport syndrome rat model with Col4a5 deficiency
por: Namba, Masumi, et al.
Publicado: (2021)

The Contribution of COL4A5 Splicing Variants to the Pathogenesis of X-Linked Alport Syndrome
por: Yamamura, Tomohiko, et al.
Publicado: (2022)

ProtExA: A tool for post-processing proteomics data providing differential expression metrics, co-expression networks and functional analytics
por: Minadakis, George, et al.
Publicado: (2020)

New frontiers to cure Alport syndrome: COL4A3 and COL4A5 gene editing in podocyte-lineage cells
por: Daga, Sergio, et al.
Publicado: (2019)

Clinical Manifestations of Alport Syndrome-Diffuse Leiomyomatosis Patients With Contiguous Gene Deletions in COL4A6 and COL4A5
por: Zhou, Xi, et al.
Publicado: (2021)

Alport syndrome caused by a COL4A5 deletion and exonization of an adjacent AluY
por: Nozu, Kandai, et al.
Publicado: (2014)

Novel heterozygous mutation in COL4A4 responsible for Alport syndrome in a Chinese family
por: Du, Ran, et al.
Publicado: (2022)

Novel mutations of COL4A3, COL4A4, and COL4A5 genes in Chinese patients with Alport Syndrome using next generation sequence technique
por: Zhao, Xuechao, et al.
Publicado: (2019)

The Mutational Spectrum of Lynch Syndrome in Cyprus
por: Loizidou, Maria A., et al.
Publicado: (2014)

Should We Diagnose Autosomal Dominant Alport Syndrome When There Is a Pathogenic Heterozygous COL4A3 or COL4A4 Variant?
por: Savige, Judy
Publicado: (2018)

Alport Syndrome: De Novo Mutation in the COL4A5 Gene Converting Glycine 1205 to Valine
por: Antón-Martín, Pilar, et al.
Publicado: (2012)

Development of an exon skipping therapy for X-linked Alport syndrome with truncating variants in COL4A5
por: Yamamura, Tomohiko, et al.
Publicado: (2020)

The First COL4A5 Exon 41A Glycine Substitution in a Family With Alport Syndrome
por: Wang, Fang, et al.
Publicado: (2020)

Publisher Correction: Creation of X-linked Alport syndrome rat model with Col4a5 deficiency
por: Namba, Masumi, et al.
Publicado: (2021)

Genetic and molecular dynamics analysis of two variants of the COL4A5 gene causing Alport syndrome
por: Liang, Lei, et al.
Publicado: (2023)

Genotype-Phenotype Correlations for Pathogenic COL4A3–COL4A5 Variants in X-Linked, Autosomal Recessive, and Autosomal Dominant Alport Syndrome
por: Savige, Judy, et al.
Publicado: (2022)

Combination of a 15-SNP Polygenic Risk Score and Classical Risk Factors for the Prediction of Breast Cancer Risk in Cypriot Women
por: Yiangou, Kristia, et al.
Publicado: (2021)

Alport Syndrome With Kidney Cysts Is Still Alport Syndrome
por: Savige, Judy, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_egtq8dolg4hm6u6sqdkii0vvp7